Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 16/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 2/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.48 |
| ▸ | PDE5A | O76074 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL583294 | 0.90 | PDE4B (0.50) | PDE4BTP53MAPTPDE4APDE4C | |
| SCHEMBL583341 | 0.80 | PDE4B (0.52) | PDE4BTP53MAPTPDE4APDE4C | |
| SCHEMBL582621 | 0.77 | PDE4B (0.58) | PDE4BPDE5A | |
| SCHEMBL582251 | 0.77 | PDE4B (0.49) | PDE4BTP53MAPTPDE4APDE4C | |
| SCHEMBL582252 | 0.77 | PDE4B (0.49) | PDE4BTP53MAPTPDE4APDE4C | |
| SCHEMBL582993 | 0.77 | PDE4B (0.49) | PDE4BTP53MAPTPDE4APDE4C | |
| SCHEMBL582469 | 0.77 | PDE4B (0.54) | PDE4BTP53MAPTPDE4APDE4C | |
| SCHEMBL583482 | 0.77 | PDE4B (0.65) | PDE4B | |
| SCHEMBL582892 | 0.76 | PDE4B (0.70) | PDE4BTP53MAPTPDE5A | |
| SCHEMBL582847 | 0.75 | PDE4B (0.71) | PDE4BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2124944-B1 | Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors | RANBAXY LAB LTD (IN) | 2012-02-15 | — | — | EP | claimed |
| US-20100292196-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-18 | — | — | US | claimed |
| US-8420666-B2 | Pyrazolo (3, 4-B) pyridine derivatives as phosphodiesterase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2013-04-16 | — | — | US | disclosed |
| EP-2124944-B1 | Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors | RANBAXY LAB LTD (IN) | 2012-02-15 | — | — | EP | disclosed |
| US-20100292196-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292196-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE4A, PDE3A | PDE4B 5/4885TP53 1157/4885MAPT 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.